To determine if the proliferative effects of PPARD inhibitors was specific to the RXRA-mutant-driven proliferation, we utilized an organoid line we established from a carcinogen-induced bladder tumor, called MCB6C, which shows robust growth in EGF deplete media, but does not harbor the RXRA mutation (not shown). This evidence concerns the gene PPARD and urinary bladder neoplasm.